Digestive Health

As patents expire, the development of biosimilars may increase, opening up new opportunities to compare efficacies of these drugs.

Similarities between the symptoms of Clostridioides difficile infection and Crohn disease may cause confusion for health care providers.

The results of the INSPIRE trial demonstrated that 20.3% of individuals receiving risankizumab (Skyrizi) achieved clinical remission compared to 6.2% of individuals who received the placebo.

Different guidelines have notable differences between equivalency dosing of proton pump inhibitors (PPI), resulting in confusion and a lack of confidence between medical professionals recommending one PPI over another.

Purine metabolite xanthine, found in caffeinated beverages and food, affect cell differentiation, and new study results may lead to more knowledge about why diseases such as IBD develop.

Educate patients about the use of nonprescription products for digestive issues, and encourage them to seek further medical care when warrented.

Few Americans' diets meet the FDA's dietary guidelines; minerals and vitamins can pick up the slack to contribute to digestive health.

The popularity of intermittent fasting, or time-restricted eating patterns, may not help control weight as well as other dieting methods.

Products range from natural eye relief to sleep aid.

Analysis indicates that for individuals older than aged 40 years, the risk is cumulative and greatest 1 to 2 years after use.

The relative abundance of gram-negative Bacteroidetes to other phyla, such as gram-positive Firmicutes, is essential to maintain biodiversity and human gut health.

Patients with type 2 diabetes may lower their risk of developing severe neurological disorders like Alzheimer disease by taking certain anti-diabetic medications alongside daily insulin.

In the trial, randomized patients with UC who received corticosteroids at maintenance baseline were able to eliminate the use of corticosteroids by week 200.

The VEGA study is the first randomized, controlled trial to evaluate the efficacy and safety of combination therapy with an interleukin (IL)-23p19 subunit antagonist (guselkumab) and a tumor necrosis factor-alpha (TNFα) antagonist (golimumab) in UC.

Sacrosidase was approved by the FDA to treat congenital sucrase-isomaltase deficiency, a condition that inhibits people from breaking down sucrose.

Ozanimod (Zeposia) is indicated for the treatment of multiple sclerosis and moderately to severely active ulcerative colitis in adults.

Risankizumab-rzaa is the first and only specific IL-23 inhibitor approved to treat moderately to severely active Crohn disease in adults.

Scientists found that inhibiting certain immune system receptors could treat colon cancer and other diseases of the gastrointestinal tract.

Researchers studying the gut microbiome found that fiber supplements of any kind could improve gut health.

Health care professionals need to work closely with patients in understanding polypharmacy and the risk/benefit of pharmacotherapy.

The ability of an anti-interleukin-23 antibody to bind to key immune system components may help neutralize a key driver of inflammation right at its cellular source.

Senokot-S is indicated for constipation relief.

Investigators found that the health risks linked to the condition known as metabolic syndrome could be diminished by green tea’s anti-inflammatory benefits in the gut.

Submissions are based on 3 phase 3 clinical trials showing that the drug achieved the co-primary endpoints of clinical remission and endoscopic response as induction and maintenance treatment.

NauseaCalm relieves nausea and vomiting to treat the symptoms of upset stomach and the stomach flu.

It’s common practice to recommend heart failure patients follow low sodium diets, but research has shown this type of diet may worsen patient health for certain forms of the condition.

Dupilumab (Dupixent) is the first medicine to improve signs of eosinophilic esophagitis and support weight gain in children ages 1 to 11, for whom there are no currently approved treatments.

Indications for adalimumab include ankylosing spondylitis, Crohn disease, chronic plaque psoriasis, juvenile idiopathic arthritis, moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

People have been taking probiotics to support digestive health for centuries, but researchers in the pulmonary field have turned their attention toward how microbiome science can be used to support the lungs.

Risankizumab-rzaa (Skyrizi) is the first and only specific interleukin-23 inhibitor approved for the treatment of adults with moderately to severely active Crohn disease.